Cell-Based Assays Under FDA Scrutiny: Lessons from Recent CRLs
About This Webcast
“Dear Sponsor, we regret to inform you…”—not the message any drug developer wants to receive. Cell-based assays have repeatedly appeared in FDA Complete Response Letters (CRLs). So, what is going wrong, and how can development teams better prepare? In this webinar, we'll examine recent FDA CRLs to identify the most common deficiencies related to cell-based assays in regulatory submissions. Drawing directly from FDA observations and current guidance documents, we'll translate these findings into practical recommendations that can help developers build more robust assays, strengthen validation strategies, and reduce regulatory risk. Whether you're developing biologics, cell therapies, or gene therapies, this session will provide insight into what the FDA expects and how to avoid the pitfalls that continue to delay regulatory approvals. What You'll Learn The most common cell-based assay deficiencies identified in recent FDA CRLs. The regulatory expectations behind these FDA observations. Practical strategies to strengthen cell-based assay development, validation, and regulatory readiness.
Speakers
Reginald Clayton, PhD
Head of Biosafety , Solvias
Dr. Reginald Clayton is the Head of Biosafety at Solvias. Reg has worked in various positions in the pharmaceuticals sector for around 25 years, including as a Project Leader for small molecule antivirals discovery at Johnson & Johnson, Belgium; as Principal Scientist for Virology in the Field Development group at BioReliance (Merck, Glasgow) and as a VP of Serology and Disease Screening in the medical devices sector. Reg is a subject matter expert in virology, infectious diseases and cell-based assays and holds a PhD from the University of Glasgow
Daniel Galbraith, PhD
Chief Scientific Officer , Solvias
Daniel Galbraith is an innovation driver and science leader in the biotechnology industry. He currently serves as CSO at Solvias, a global CRO in the small and large molecule space. Before transitioning to industry, Daniel spent six years conducting post-doctoral research in clinical virology. Since 1996, he has held several senior roles in the CRO sector, contributing to the pre-clinical and clinical development of vaccines and gene therapy vectors. Prior to joining Solvias, he was Head of Technology Management and Novel Products at Merck, where he led global initiatives applying innovative technologies to bring new ATMPs to the clinic. Earlier in his career, Daniel founded BioOutsource, a company specializing in the characterization of biotechnology products, where he served as Chief Scientist and oversaw R&D and the development of a new U.S. site. Daniel also has two external positions: he is a member of the Scientific Advisory Board for Refeyn, a university spin-out focused on technology innovation, and serves as Chair of Glen Clova Scientific, an early-stage vaccine development company.
Patrick Lavery
Content Marketing Editor , Contract Pharma
Patrick Lavery is the Content Marketing Editor for Contract Pharma. He joined the Contract Pharma team in January 2026. Patrick has more than 15 years of media experience across numerous formats, including online, print, and broadcast, and transitioned to covering healthcare, pharma, and life sciences news exclusively in 2023. For Contract Pharma, he contributes to breaking news and conference coverage, conducts exclusive interviews, and produces “The Friday Brief,” a weekly video wrap-up of industry headlines for the Contract Pharma website and newsletter.